Clinics and Other Outpatient Facility Services Handbook - TMHP
Clinics and Other Outpatient Facility Services Handbook - TMHP
Clinics and Other Outpatient Facility Services Handbook - TMHP
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 2 - JANUARY 2013<br />
• Insulin<br />
• Digoxin—procedure code J1160<br />
• Norepinephrine bitartrate<br />
• Mannitol—procedure code J2150<br />
• Procaine<br />
• Protamine—procedure code J2720<br />
• Saline—procedure code A4216 or A4217<br />
• Hydrocortisone sodium succinate—procedure code J1720<br />
• Verapamil<br />
Medically necessary drugs that are not included in the composite rate may be separately reimbursed<br />
when provided by <strong>and</strong> administered in the dialysis facility by facility staff. Staff time <strong>and</strong> supplies used<br />
to administer the drugs are included in the composite rate. Examples include, but are not limited to, the<br />
following:<br />
• Antibiotics, except when prescribed for clients to treat infections or peritonitis related to peritoneal<br />
dialysis<br />
• Hematinics<br />
• Anabolics<br />
• Muscle relaxants<br />
• Analgesics<br />
• Sedatives<br />
• Tranquilizers<br />
• Erythropoietin<br />
• Thrombolytics used to declot central venous catheters<br />
• Intravenous levocarnitine (procedure code J1955), for ESRD clients who have been on dialysis for a<br />
minimum of three months with one of the following indications (All other indications for levocarnitine<br />
are not covered.):<br />
• Carnitine deficiency, defined as a plasma free carnitine level less than 40 micromoles per liter.<br />
• Signs <strong>and</strong> symptoms of erythropoietin-resistant anemia that has not responded to st<strong>and</strong>ard<br />
erythropoietin with iron replacement, <strong>and</strong> for which other causes have been investigated <strong>and</strong><br />
adequately treated.<br />
• Hypotension on hemodialysis that interferes with delivery of the intended dialysis despite application<br />
of usual measures deemed appropriate (e.g., fluid management) (such episodes of<br />
hypotension must have occurred during at least two dialysis treatments in a 30-day period).<br />
Note: Continued use of levocarnitine is not covered if improvement has not been demonstrated<br />
within six months of the initiation of treatment.<br />
The ordering physician must maintain documentation in the client’s medical record to support medical<br />
necessity.<br />
OP-24<br />
CPT ONLY - COPYRIGHT 2012 AMERICAN MEDICAL ASSOCIATION. ALL RIGHTS RESERVED.